Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.

Marc-Antoine LepageNicholas RozzaRichard Kremer Ami Grunbaum

Published in: Clinical toxicology (Philadelphia, Pa.) (2021)

No patients reached presumed therapeutic LPV concentrations despite experiencing side effects and exceeding cholestasis and dyslipidemia toxicity thresholds. This raises concerns for the safety and effectiveness of LPV/r. Clinicians should consider closely monitoring for side effects and not necessarily attribute them to COVID-19.

Keyphrases

end stage renal disease
coronavirus disease
ejection fraction
sars cov
randomized controlled trial
systematic review
peritoneal dialysis
prognostic factors
palliative care
respiratory syndrome coronavirus